



Lab No. : LAK/11-03-2023/SR7391614
 Patient Name : SAPTADIPA NATH
 Age : 33 Y 0 M 20 D
 Gender : F

Lab Add. : Newtown, Kolkata-700156
 Ref Dr. : Dr.MEDICAL OFFICER
 Collection Date: 11/Mar/2023 10:28AM
 Report Date : 11/Mar/2023 05:12PM



Test Name	Result	Unit	Bio Ref. Interval	Method
-----------	--------	------	-------------------	--------

[PDF Attached](#)

GLYCATED HAEMOGLOBIN (HBA1C) , EDTA WHOLE BLOOD

GLYCATED HEMOGLOBIN (HBA1C)	4.7	%	***FOR BIOLOGICAL REFERENCE INTERVAL DETAILS , PLEASE REFER TO THE BELOW MENTIONED REMARKS/NOTE WITH ADDITIONAL CLINICAL INFORMATION ***	
HbA1c (IFCC)	28.0	mmol/mol		HPLC

Clinical Information and Laboratory clinical interpretation on Biological Reference Interval:

Low risk / Normal / non-diabetic : <5.7% (NGSP) / < 39 mmol/mol (IFCC)
 Pre-diabetes/High risk of Diabetes : 5.7%- 6.4% (NGSP) / 39 - < 48 mmol/mol (IFCC)
 Diabetics-HbA1c level : >= 6.5% (NGSP) / > 48 mmol/mol (IFCC)

Analyzer used : Bio-Rad-VARIANT TURBO 2.0
 Method : HPLC Cation Exchange

Recommendations for glycemic targets

- Ø Patients should use self-monitoring of blood glucose (SMBG) and HbA1c levels to assess glycemic control.
- Ø The timing and frequency of SMBG should be tailored based on patients' individual treatment, needs, and goals.
- Ø Patients should undergo HbA1c testing at least twice a year if they are meeting treatment goals and have stable glycemic control.
- Ø If a patient changes treatment plans or does not meet his or her glycemic goals, HbA1c testing should be done quarterly.
- Ø For most adults who are not pregnant, HbA1c levels should be <7% to help reduce microvascular complications and macrovascular disease . Action suggested >8% as it indicates poor control.
- Ø Some patients may benefit from HbA1c goals that are stringent.

Result alterations in the estimation has been established in many circumstances, such as after acute/ chronic blood loss, for example, after surgery, blood transfusions, hemolytic anemia, or high erythrocyte turnover; vitamin B₁₂/ folate deficiency, presence of chronic renal or liver disease; after administration of high-dose vitamin E / C; or erythropoietin treatment.

Reference: Glycated hemoglobin monitoring BMJ 2006; 333:586-8

References:

1. Chamberlain JJ, Rhinehart AS, Shaefer CF, et al. Diagnosis and management of diabetes: synopsis of the 2016 American Diabetes Association Standards of Medical Care in Diabetes. Ann Intern Med. Published online 1 March 2016. doi:10.7326/M15-3016.
2. Mosca A, Goodall I, Hoshino T, Jeppsson JO, John WG, Little RR, Miedema K, Myers GL, Reinauer H, Sacks DB, Weykamp CW. International Federation of Clinical Chemistry and Laboratory Medicine, IFCC Scientific Division. Global standardization of glycated hemoglobin measurement: the position of the IFCC Working Group. Clin Chem Lab Med. 2007;45(8):1077-1080.

Dr NEEPA CHOWDHURY
 MBBS MD (Biochemistry)
 Consultant Biochemist

Lab No. : SR7391614 Name : SAPTADIPA NATH Age/G : 33 Y 0 M 20 D / F Date : 11-03-2023

SODIUM, BLOOD , GEL SERUM					
SODIUM,BLOOD	141.00	mEq/L	132 - 146 mEq/L	ISE INDIRECT	
*CHLORIDE, BLOOD , .					
CHLORIDE,BLOOD	104.00	mEq/L	99-109 mEq/L	ISE INDIRECT	
CREATININE, BLOOD , GEL SERUM					
CREATININE,BLOOD	0.65	mg/dL	0.5-1.1 mg/dL	Jaffe, alkaline picrate, kinetic	
PHOSPHORUS-INORGANIC, BLOOD , GEL SERUM					
PHOSPHORUS-INORGANIC,BLOOD	3.4	mg/dL	2.4-5.1 mg/dL	Phosphomolybdate/UV	
THYROID PANEL (T3, T4, TSH) , GEL SERUM					
T3-TOTAL (TRI IODOTHYRONINE)	1.06	ng/ml	0.60-1.81 ng/ml	CLIA	
T4-TOTAL (THYROXINE)	9.7	µg/dL	3.2-12.6 µg/dL	CLIA	
TSH (THYROID STIMULATING HORMONE)	3.37	µIU/mL	0.55-4.78 µIU/mL	CLIA	

Serum TSH levels exhibit a diurnal variation with the peak occurring during the night and the nadir, which approximates to 50% of the peak value, occurring between 1000 and 1600 hours.[1,2]

References:

- Bugalho MJ, Domingues RS, Pinto AC, Garrao A, Catarino AL, Ferreira T, Limbert E and Sobrinho L. Detection of thyroglobulin mRNA transcripts in peripheral blood of individuals with and without thyroid glands: evidence for thyroglobulin expression by blood cells. *Eur J Endocrinol* 2001;145:409-13.
- Bellantone R, Lombardi CP, Bossola M, Ferrante A, Princi P, Boscherini M et al. Validity of thyroglobulin mRNA assay in peripheral blood of postoperative thyroid carcinoma patients in predicting tumor recurrence varies according to the histologic type: results of a prospective study. *Cancer* 2001;92:2273-9.

BIOLOGICAL REFERENCE INTERVAL: [ONLY FOR PREGNANT MOTHERS]

Trimester specific TSH LEVELS during pregnancy:

FIRST TRIMESTER: 0.10 – 3.00 µ IU/mL

SECOND TRIMESTER: 0.20 -3.50 µ IU/mL

THIRD TRIMESTER : 0.30 -3.50 µ IU/mL

References:

- Erik K. Alexander, Elizabeth N. Pearce, Gregory A. Brent, Rosalind S. Brown, Herbert Chen, Chrysoula Dosiou, William A. Grobman, Peter Laurberg, John H. Lazarus, Susan J. Mandel, Robin P. Peeters, and Scott Sullivan. *Thyroid*. Mar 2017.315-389. <http://doi.org/10.1089/thy.2016.0457>
- Kalra S, Agarwal S, Aggarwal R, Ranabir S. Trimester-specific thyroid-stimulating hormone: An indian perspective. *Indian J Endocr Metab* 2018;22:1-4.


POTASSIUM, BLOOD , GEL SERUM					
POTASSIUM,BLOOD	4.00	mEq/L	3.5-5.5 mEq/L	ISE INDIRECT	
UREA,BLOOD					
UREA,BLOOD	19.3	mg/dL	19-49 mg/dL	Urease with GLDH	

Lab No. : SR7391614

Name : SAPTADIPA NATH

Age/G : 33 Y 0 M 20 D / F

Date : 11-03-2023



Dr NEEPA CHOWDHURY
MBBS MD (Biochemistry)
Consultant Biochemist



Lab No. : SR7391614 Name : SAPTADIPA NATH Age/G : 33 Y 0 M 20 D / F Date : 11-03-2023

CALCIUM, BLOOD

CALCIUM,BLOOD	9.60	mg/dL	8.7-10.4 mg/dL	Arsenazo III
---------------	------	-------	----------------	--------------

URIC ACID, BLOOD , GEL SERUM

URIC ACID,BLOOD	4.50	mg/dL	2.6-6.0 mg/dL	Uricase/Peroxidase
-----------------	------	-------	---------------	--------------------

TOTAL PROTEIN [BLOOD] ALB:GLO RATIO , .

TOTAL PROTEIN	8.10	g/dL	5.7-8.2 g/dL	BIURET METHOD
ALBUMIN	4.5	g/dL	3.2-4.8 g/dL	BCG Dye Binding
GLOBULIN	3.60	g/dl	1.8-3.2 g/dl	Calculated
AG Ratio	1.25		1.0 - 2.5	Calculated

Dr. SUPARBA CHAKRABARTI
 MBBS, MD(BIOCHEMISTRY)
 Consultant Biochemist



Lab No. : SR7391614 Name : SAPTADIPA NATH Age/G : 33 Y 0 M 20 D / F Date : 11-03-2023

ESR (ERYTHROCYTE SEDIMENTATION RATE) , EDTA WHOLE BLOOD

1stHour	16	mm/hr	0.00 - 20.00 mm/hr	Westergren
---------	----	-------	--------------------	------------

□

Dr Mansi Gulati
 Consultant Pathologist
 MBBS, MD, DNB (Pathology)



Lab No. : SR7391614 Name : SAPTADIPA NATH Age/G : 33 Y 0 M 20 D / F Date : 11-03-2023

URINE ROUTINE ALL, ALL , URINE

PHYSICAL EXAMINATION

COLOUR PALE YELLOW
 APPEARANCE SLIGHTLY HAZY

CHEMICAL EXAMINATION

pH	7.0	4.6 - 8.0	Dipstick (triple indicator method)
SPECIFIC GRAVITY	1.005	1.005 - 1.030	Dipstick (ion concentration method)
PROTEIN	NOT DETECTED	NOT DETECTED	Dipstick (protein error of pH indicators)/Manual
GLUCOSE	NOT DETECTED	NOT DETECTED	Dipstick (glucose-oxidase-peroxidase method)/Manual
KETONES (ACETOACETIC ACID, ACETONE)	NOT DETECTED	NOT DETECTED	Dipstick (Legals test)/Manual
BLOOD	NOT DETECTED	NOT DETECTED	Dipstick (pseudoperoxidase reaction)
BILIRUBIN	NEGATIVE	NEGATIVE	Dipstick (azo-diazo reaction)/Manual
UROBILINOGEN	NEGATIVE	NEGATIVE	Dipstick (diazonium ion reaction)/Manual
NITRITE	NEGATIVE	NEGATIVE	Dipstick (Griess test)
LEUCOCYTE ESTERASE	NEGATIVE	NEGATIVE	Dipstick (ester hydrolysis reaction)

MICROSCOPIC EXAMINATION

LEUKOCYTES (PUS CELLS)	0-1	/hpf	0-5	Microscopy
EPITHELIAL CELLS	4-6	/hpf	0-5	Microscopy
RED BLOOD CELLS	NOT DETECTED	/hpf	0-2	Microscopy
CAST	NOT DETECTED		NOT DETECTED	Microscopy
CRYSTALS	NOT DETECTED		NOT DETECTED	Microscopy
BACTERIA	PRESENT(+)		NOT DETECTED	Microscopy
YEAST	NOT DETECTED		NOT DETECTED	Microscopy

Note:

- All urine samples are checked for adequacy and suitability before examination.
- Analysis by urine analyzer of dipstick is based on reflectance photometry principle. Abnormal results of chemical examinations are confirmed by manual methods.
- The first voided morning clean-catch midstream urine sample is the specimen of choice for chemical and microscopic analysis.
- Negative nitrite test does not exclude urinary tract infections.
- Trace proteinuria can be seen in many physiological conditions like exercise, pregnancy, prolonged recumbency etc.
- False positive results for glucose, protein, nitrite, urobilinogen, bilirubin can occur due to use of certain drugs, therapeutic dyes, ascorbic acid, cleaning agents used in urine collection container.
- Discrepancy between results of leukocyte esterase and blood obtained by chemical methods with corresponding pus cell and red blood cell count by microscopy can occur due to cell lysis.
- Contamination from perineum and vaginal discharge should be avoided during collection, which may falsely elevate epithelial cell count and show presence of bacteria and/or yeast in the urine.

CBC WITH PLATELET (THROMBOCYTE) COUNT , EDTA WHOLE BLOOD

HEMOGLOBIN	12.6	g/dL	12 - 15	PHOTOMETRIC
WBC	5.8	*10 ³ /μL	4 - 10	DC detection method
RBC	4.72	*10 ⁶ /μL	3.8 - 4.8	DC detection method
PLATELET (THROMBOCYTE) COUNT	170	*10 ³ /μL	150 - 450*10 ³ /μL	DC detection method/Microscopy

DIFFERENTIAL COUNT

NEUTROPHILS	43	%	40 - 80 %	Flowcytometry/Microscopy
LYMPHOCYTES	43	%	20 - 40 %	Flowcytometry/Microscopy
MONOCYTES	11	%	2 - 10 %	Flowcytometry/Microscopy
EOSINOPHILS	02	%	1 - 6 %	Flowcytometry/Microscopy
BASOPHILS	01	%	0-0.9%	Flowcytometry/Microscopy

CBC SUBGROUP

Lab No. : LAK/11-03-2023/SR7391614

Page 6 of 13



Lab No. : SR7391614	Name : SAPTADIPA NATH	Age/G : 33 Y 0 M 20 D / F		Date : 11-03-2023
HEMATOCRIT / PCV	39.4	%	36 - 46 %	Calculated
MCV	83.4	fl	83 - 101 fl	Calculated
MCH	26.7	pg	27 - 32 pg	Calculated
MCHC	32.0	gm/dl	31.5-34.5 gm/dl	Calculated
RDW - RED CELL DISTRIBUTION WIDTH	14.6	%	11.6-14%	Calculated
PDW-PLATELET DISTRIBUTION WIDTH	36.8	fL	8.3 - 25 fL	Calculated
MPV-MEAN PLATELET VOLUME	15.3		7.5 - 11.5 fl	Calculated

BLOOD GROUP ABO+RH [GEL METHOD] , EDTA WHOLE BLOOD

ABO	O	Gel Card
RH	POSITIVE	Gel Card

TECHNOLOGY USED: GEL METHOD

ADVANTAGES :

- Gel card allows simultaneous forward and reverse grouping.
- Card is scanned and record is preserved for future reference.
- Allows identification of Bombay blood group.
- Daily quality controls are run allowing accurate monitoring.

Historical records check not performed.

□

DR. NEHA GUPTA
MD, DNB (Pathology)
Consultant Pathologist



Lab No. : SR7391614 Name : SAPTADIPA NATH Age/G : 33 Y 0 M 20 D / F Date : 11-03-2023

GLUCOSE, FASTING , BLOOD, NAF PLASMA

GLUCOSE,FASTING	80	mg/dL	Impaired Fasting-100-125 . Diabetes- >= 126. Fasting is defined as no caloric intake for at least 8 hours.	Gluc Oxidase Trinder
-----------------	----	-------	---	----------------------

In the absence of unequivocal hyperglycemia, diagnosis requires two abnormal test results from the same sample or in two separate test samples.

Reference :
ADA Standards of Medical Care in Diabetes – 2020. Diabetes Care Volume 43, Supplement 1.

LIPID PROFILE , GEL SERUM

CHOLESTEROL-TOTAL	142.00	mg/dL	Desirable: < 200 mg/dL Borderline high: 200-239 mg/dL High: > or =240 mg/dL	Enzymatic
TRIGLYCERIDES	70.00	mg/dL	Normal:: < 150, BorderlineHigh::150-199, High:: 200-499, VeryHigh::>500	GPO-Trinder
HDL CHOLESTEROL	41.00	mg/dl	< 40 - Low 40-59- Optimum 60 - High	Elimination/catalase
LDL CHOLESTEROL DIRECT	87.0	mg/dL	OPTIMAL : <100 mg/dL, Near optimal/ above optimal : 100-129 mg/dL, Borderline high : 130-159 mg/dL, High : 160-189 mg/dL, Very high : >=190 mg/dL	Calculated
VLDL	14	mg/dl	< 40 mg/dl	Calculated
CHOL HDL Ratio	3.5		LOW RISK 3.3-4.4 AVERAGE RISK 4.47-7.1 MODERATE RISK 7.1-11.0 HIGH RISK >11.0	Calculated

Reference: National Cholesterol Education Program. Executive summary of the third report of The National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. May 16 2001;285(19):2486-97.

□

DR. ANANNYA GHOSH
MBBS, MD (Biochemistry)
Consultant Biochemist

Lab No. : SR7391614 Name : SAPTADIPA NATH Age/G : 33 Y 0 M 20 D / F Date : 13-03-2023

DEPARTMENT OF CYTOPATHOLOGY

PAP SMEAR REPORT

Lab No : P - 860/23

Reporting System : The 2014 Bethesda System
Specimen : Conventional Cervical Pap smear.

Specimen Adequacy : Satisfactory for evaluation :
A satisfactory squamous component is present.
Endocervical or transformation zone component : Absent.
Obscuring elements : Absent.

General Categorization :
Negative for Intraepithelial Lesion / Malignancy (NILM).

Non-Neoplastic Findings :
Mild inflammation is noted in the background.

INTERPRETATION / RESULTS : Negative for Intraepithelial Lesion / Malignancy (NILM).

Note : Pap smear cytology is a screening procedure. Findings should be correlated with colposcopic/local examination and ancillary findings. As per current recommendation, women aged 30-65 years should be screened with both the HPV test and the Pap test, called "co-testing," as the preferred strategy. Screening with the Pap test alone every 3 years is still acceptable.

Ancillary Testing – For HPV testing using PCR from the same sample (only in case of LBC) request should come within 15 days from the reporting date.

***Report relates to the item tested only.

□



DR. NEHA GUPTA
MD, DNB (Pathology)
Consultant Pathologist

Lab No. : LAK/11-03-2023/SR7391614
Patient Name : SAPTADIPA NATH
Age : 33 Y 0 M 20 D
Gender : F

Lab Add. :
Ref Dr. : Dr.MEDICAL OFFICER
Collection Date:
Report Date : 11/Mar/2023 02:58PM



DEPARTMENT OF CARDIOLOGY
REPORT OF E.C.G.

DATA		
HEART RATE	59	Bpm
PR INTERVAL	124	Ms
QRS DURATION	84	Ms
QT INTERVAL	404	Ms
QTC INTERVAL	404	Ms
AXIS		
P WAVE	0	Degree
QRS WAVE	50	Degree
T WAVE	20	Degree
IMPRESSION	: Sinus bradycardia, otherwise normal ECG.	

ACRay

Dr. A C RAY
Department of Non-invasive
Cardiology

Lab No. : LAK/11-03-2023/SR7391614
Patient Name : SAPTADIPA NATH
Age : 33 Y 0 M 20 D
Gender : F

Lab Add. :
Ref Dr. : Dr.MEDICAL OFFICER
Collection Date:
Report Date : 11/Mar/2023 03:25PM



ULTRASONOGRAPHY OF WHOLE ABDOMEN

LIVER :

Liver is normal in size (measures 89.53 mm) having normal shape, regular smooth outline and of homogeneous echotexture. No focal parenchymal lesion is evident. Intrahepatic biliary radicles are not dilated. Branches of portal vein are normal.

COMMON BILE DUCT :

The common bile duct is not dilated. The common duct at porta hepatis, measures 3.24 mm. in diameter.

PORTAL VEIN :

Portal vein at porta, measures 10.13 mm. and is of normal calibre.

GALL BLADDER :

Gallbladder is physiologically distended. Wall thickness appears normal. No intraluminal pathology (Calculi/mass) could be detected.

PANCREAS :

Echogenicity appears within normal limits, without any focal lesion. Shape, size & position appears normal. No Calcular disease noted. Pancreatic duct is not dilated. No peri-pancreatic collection of fluid noted.

SPLEEN :

Spleen is normal in size (measures 84.02 mm). Homogenous and smooth echotexture without any focal lesion. Splenic vein at hilum appears normal. No definite collaterals could be detected.

KIDNEYS :

The Kidneys are normal in position, size, shape, outline and echotexture. The Corticomedullary differentiation is maintained. No calculus, hydronephrosis or mass is noted. The perinephric region shows no abnormal fluid collection.

Right Kidney length 105 mm. & Left Kidney length 110 mm.

URETER: Both ureters are not dilated. No calculus is noted in either side.

PERITONEUM & RETROPERITONEUM: The aorta and IVC are normal. Lymph nodes are not enlarged. No free fluid is seen in peritoneum.

URINARY BLADDER :

Urinary bladder is distended, wall thickness appeared normal. No intraluminal pathology (calculi/mass) could be detected.

UTERUS :

It is normal in shape, size (68 x 34 x 42 mm) and echopattern. No focal myometrial lesion is seen. Endometrial echo is in midline. Endometrial thickness is 7.46 mm. Endometrial cavity is empty. Cervix is normal.

Lab No. : LAK/11-03-2023/SR7391614
Patient Name : SAPTADIPA NATH
Age : 33 Y 0 M 20 D
Gender : F

Lab Add. :
Ref Dr. : Dr.MEDICAL OFFICER
Collection Date:
Report Date : 11/Mar/2023 03:25PM



ADNEXA: No adnexal SOL is noted.

OVARIES :

Ovaries are normal in size, shape, position, margin and echotexture.

Right ovary measures : 26.46 x 18.69 mm.

Left Ovary measures : 23.65 x 15.24 mm.

POD : No fluid is seen.

IMPRESSION :

- **Study within normal limits.**

Please correlate clinically.

Kindly note

∅ Ultrasound is not the modality of choice to rule out subtle bowel lesion.

∅ Please Intimate us for any typing mistakes and send the report for correction within 7 days.

∅ The science of Radiological diagnosis is based on the interpretation of various shadows produced by both the normal and abnormal tissues and are not always conclusive.

Further biochemical and radiological investigation & clinical correlation is required to enable the clinician to reach the final diagnosis.

The report and films are not valid for medico-legal purpose.

Patient Identity not verified.

Dr. P.C.Jain
MD Radiodiagnosis

Lab No. : LAK/11-03-2023/SR7391614
Patient Name : SAPTADIPA NATH
Age : 33 Y 0 M 20 D
Gender : F

Lab Add. :
Ref Dr. : Dr.MEDICAL OFFICER
Collection Date:
Report Date : 11/Mar/2023 03:06PM



X-RAY REPORT OF CHEST (PA)

FINDINGS :

No active lung parenchymal lesion is seen.
Both the hila are normal in size, density and position.
Mediastinum is in central position. Trachea is in midline.
Domes of diaphragm are smoothly outlined. Position is within normal limits.
Lateral costo-phrenic angles are clear.
The cardio-thoracic ratio is normal.
Bony thorax reveals no definite abnormality.

IMPRESSION :

Normal study.

**Please Intimate us for any typing mistakes and send the report for correction within 7 days.

Dr. P.C.Jain
MD Radiodiagnosis

Patient Data

Sample ID: C02135998299
 Patient ID: SR7391614
 Name:
 Physician:
 Sex:
 DOB:

Analysis Data

Analysis Performed: 11/MAR/2023 16:22:16
 Injection Number: 5575U
 Run Number: 131
 Rack ID: 0003
 Tube Number: 5
 Report Generated: 11/MAR/2023 16:38:32
 Operator ID: ASIT

Comments:

Peak Name	NGSP %	Area %	Retention Time (min)	Peak Area
A1a	---	1.2	0.160	22847
A1b	---	0.7	0.220	13963
F	---	0.9	0.273	17397
LA1c	---	1.6	0.403	30414
A1c	4.7	---	0.510	73004
P3	---	3.2	0.791	62711
P4	---	1.1	0.868	22078
Ao	---	87.5	0.989	1703763

Total Area: 1,946,176

HbA1c (NGSP) = 4.7 % HbA1c (IFCC) = 28 mmol/mol

